• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

    10/11/24 4:02:13 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email
    SC 13G 1 crbp1011241sc13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Corbus Pharmaceuticals Holdings, Inc.
    (Name of Issuer)
     
    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

      21833P301  
      (CUSIP Number)  
     
    September 30, 2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      o Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No.  21833P301
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Capital Advisors LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,115,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,115,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,115,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

     Page 2 of 8 
     

     

    CUSIP No.  21833P301
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Octagon Investments Master Fund LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,115,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,115,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,115,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    OO, PN

     

     Page 3 of 8 
     

     

    CUSIP No.  21833P301
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ting Jia

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)o

    (b)o

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    China

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,115,000

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,115,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,115,000

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    o

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    HC, IN

     

     Page 4 of 8 
     

     

    Item 1(a). Name of Issuer:
       
       Corbus Pharmaceuticals Holdings, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
       500 River Ridge Drive, Norwood, MA 02062
       
    Item 2(a). Name of Person Filing:
       
      

    This statement is being jointly filed by:

     

    Octagon Capital Advisors LP ("Octagon")

    Octagon Investments Master Fund LP ("Master Fund")

    Ting Jia, as the principal beneficial owner of Octagon ("Mr. Jia")

     

    Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

     

    Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer's Common Shares directly owned by the Master Fund.

     

       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
       The address of the business office of each of the Reporting Persons is 654 Madison Avenue, 21st Floor, New York, NY 10065
       
    Item 2(c). Citizenship:
       
       Octagon is a Delaware limited partnership.  The Master Fund is an exempted limited partnership established in the Cayman Islands.  Mr. Jia is a Chinese citizen.
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, $0.0001 par value (the “Common Shares”)
       
    Item 2(e). CUSIP Number:  21833P301

     

     Page 5 of 8 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act;
      (b) o Bank as defined in Section 3(a)(6) of the Act;
      (c) o Insurance company as defined in Section 3(a)(19) of the Act;
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 1,115,000
       (b) Percent of Class: 9.3%
               The percentage reported on this Schedule 13G is calculated based upon 12,043,940 Common Shares outstanding as of August 2, 2024, as reported in the Form 10-Q filed by the Issuer on August 6, 2024.  
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: 0
          (ii) shared power to vote or to direct the vote: 1,115,000
          (iii) sole power to dispose or to direct the disposition of: 0
          (iv) shared power to dispose or to direct the disposition of: 1,115,000

     

     Page 6 of 8 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Octagon is the investment advisor to the Master Fund and other accounts.  Mr. Jia is the control person of Octagon.  The Master Fund holds the Common Shares for the benefit of its investors.  The Master Fund and Octagon, for the benefit of its investors, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     Page 7 of 8 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 11, 2024 OCTAGON CAPITAL ADVISORS LP
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member

     

     

      OCTAGON INVESTMENTS MASTER FUND LP
      By: Octagon Investments GP, LLC, its general partner
       
      /s/ Ting Jia
      Name: Ting Jia
      Title: Managing Member
         
         
     

    TING JIA

     

    /s/ Ting Jia

      Name: Ting Jia

     

     

    Pages 8 of 8

     

     

     

    Get the next $CRBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    3/6/2024$4.00 → $46.00Hold → Buy
    Jefferies
    More analyst ratings

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Corbus Pharma

      William Blair initiated coverage of Corbus Pharma with a rating of Outperform

      2/28/25 7:22:12 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corbus Pharma

      Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

      12/2/24 9:55:40 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Corbus Pharma with a new price target

      Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00

      7/30/24 6:19:42 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY. 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: May 21, 2025Time: 8:30 a.m. ETWebcast: Click here About CorbusCorbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people def

      5/8/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumors NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. "During the first quarter of 2025, we continu

      5/6/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    SEC Filings

    See more
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/19/25 8:30:10 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

      10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 4:21:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 8:30:09 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hodgson Ian claimed ownership of 25,977 shares (SEC Form 3)

      3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/18/25 4:45:04 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Smethurst Dominic sold $43,330 worth of shares (6,393 units at $6.78), decreasing direct ownership by 8% to 70,807 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/7/25 4:30:08 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Sean F. sold $24,446 worth of shares (2,792 units at $8.76), decreasing direct ownership by 4% to 73,313 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/18/25 5:40:54 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/11/24 5:34:06 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/6/24 4:00:46 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 7:48:14 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 6:41:20 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:05:29 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

      NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

      8/20/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

      NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

      2/28/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care